Effects of the Use of an Immersive Virtual Reality Device on Handwriting in Children Aged 6 to 13 With Handwriting Difficulties ( RVALIGO )

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-13
SponsorFondation Ildys

About this trial

Difficulties in learning to write affect a large number of children and can have a significant impact on their personal and professional future. To facilitate this learning process, develop fun, motivating and effective devices for the different skills involved in writing (motor skills, postural control, visual attention, letter recognition) is needing. Virtual Reality (VR) seems to be a promising tool for this purpose.

The SCED (Single Case Experimental Design) methodology is adapted to this study to evaluate the impact of VR on learning to write, as it allows a high level of evidence and is applicable to a heterogeneous population such as that affected by difficulties in learning to write. The study will include an original study of 3 children and 3 replications of 3 children each. In total, 12 children will be included in four different settings. This study will determine whether VR training can facilitate learning to write.

The main objective of this study is to evaluate the impact of immersive virtual reality training on handwriting using the Evaligo tool to assess static, kinematic and pressure parameters of handwriting in children aged 6 to 13 with handwriting difficulties according to a SCED methodology.

Eligibility criteria

Qualifiers

Age : 6-13 years

BHK: degradation score ≥ 1 standard deviation. The BHK will be administered at the time of the inclusion visit (V1) and/or child with writing difficulties in in daily activities.

Children benefiting or to benefit from rehabilitation care to improve handwriting skills.

Be able to understand instructions and complete all assessments.

Disqualifiers

Contraindications to using a virtual reality HMD

Severe visual impairment

Facial injury

Epilepsy

Trial design

Treatments tested in this trial

  • Baseline
  • Intervention

Treatment groups

12 Participants
are divided into 1 treatment group

Sponsors and collaborators

Fondation Ildys

Lead sponsor

LP3C, University of Brest

Collaborator

LaTim Laboratory

Collaborator